TRA-P2

Print

2007

TRA-P2

To evaluate the effect of SCH 530348, administered for a minimum of 1 year, with respect to the incidence of atherothrombotic events (composite of cardiovascular (CV) death, myocardial infarction (MI), stroke, or urgent coronary revascularization) in subjects with documented atherosclerotic disease receiving standard therapy.


Last Updated ( Tuesday, 25 August 2015 13:15 )